Spectral Diagnostic's loss nearly triples:
This article was originally published in Clinica
Executive Summary
Canadian cardiac diagnostics developer Spectral Diagnostics has nearly tripled its loss in fiscal 1995. In the 12 months ended March its net loss rose to Can$9 million ($6.6 million) compared with Can$3.4 million in the previous year. In the same period revenues more than doubled to Can$458,000. Spectral's marketing partner for North and South America, Dade International, has begun to sell the stratus cardiac troponin I test for the evaluation of chest pain, describing it as the first whole blood, point-of-care test for cardiac markers.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.